{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:52:34Z","timestamp":1780339954940,"version":"3.54.1"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009048","name":"Japanese Society of Clinical Neuropsychopharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015070","name":"Department of Psychiatry, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014405","name":"Centre for Addiction and Mental Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002806","name":"Discovery Eye Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010523","name":"Centre for Addiction and Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010523","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031308","name":"Watanabe Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015074","name":"Ministry of Training, Colleges and Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000241","name":"Physicians' Services Incorporated Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008884","name":"Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000064","name":"Banting and Best Diabetes Centre, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H02755"],"award-info":[{"award-number":["18H02755"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H03002"],"award-info":[{"award-number":["22H03002"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.schres.2024.05.020","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T06:18:54Z","timestamp":1717568334000},"page":"11-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The effect of second-generation antipsychotics on anxiety\/depression in patients with schizophrenia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"270","author":[{"given":"Ali","family":"Abdolizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Hosseini Kupaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Kambari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Amaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittal","family":"Korann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Torres-Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel-Teruki","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Mahavir","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Gerretsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Graff-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2024.05.020_bb0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2024.05.020_bb0010","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/schbul\/sbp148","article-title":"How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association","volume":"37","author":"Achim","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.05.020_bb0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.schres.2024.05.020_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1755-7682-6-47","article-title":"Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial","volume":"6","author":"Amr","year":"2013","journal-title":"Int. Arch. Med."},{"key":"10.1016\/j.schres.2024.05.020_bb0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-010-1783-1","article-title":"Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects","volume":"209","author":"Arakawa","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2024.05.020_bb0030","article-title":"Clozapine versus olanzapine for people with schizophrenia","volume":"2018","author":"Asenjo-Lobos","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2024.05.020_bb0035","first-page":"257","article-title":"Olanzapine in the treatment of schizophrenia: an open label comparative clinical trial from North India","volume":"43","author":"Avasthi","year":"2001","journal-title":"Indian J. Psychiatry."},{"key":"10.1016\/j.schres.2024.05.020_bb0040","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia","volume":"158","author":"Azorin","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0045","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1111\/bph.15807","article-title":"Tricyclic antipsychotics and antidepressants can inhibit \u03b15-containing GABA A receptors by two distinct mechanisms","volume":"179","author":"Bampali","year":"2022","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0050","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0055","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1021\/jm0508641","article-title":"An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression","volume":"49","author":"Becker","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.schres.2024.05.020_bb0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.schres.2024.05.020_bb0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00004714-199602000-00007","article-title":"Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients","volume":"16","author":"Blin","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jpsychires.2004.09.003","article-title":"Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life","volume":"39","author":"Braga","year":"2005","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0075","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.4088\/JCP.v66n1016","article-title":"Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study","volume":"66","author":"Brawman-Mintzer","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0080","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010677.pub2","article-title":"Benzodiazepines versus placebo for panic disorder in adults","author":"Breilmann","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2024.05.020_bb0090","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00213-004-2082-5","article-title":"Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study","volume":"178","author":"Brook","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2024.05.020_bb0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/schbul\/sbn135","article-title":"Psychiatric comorbidities and schizophrenia","volume":"35","author":"Buckley","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.05.020_bb0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/jts.20114","article-title":"The impact of posttraumatic stress disorder on quality of life and health service utilization among veterans who have schizophrenia","volume":"19","author":"Calhoun","year":"2006","journal-title":"J. Trauma. Stress"},{"key":"10.1016\/j.schres.2024.05.020_bb0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/jts.20114","article-title":"The impact of posttraumatic stress disorder on quality of life and health service utilization among veterans who have schizophrenia","volume":"19","author":"Calhoun","year":"2006","journal-title":"J. Trauma. Stress"},{"key":"10.1016\/j.schres.2024.05.020_bb0110","first-page":"9S","article-title":"Clinical practice guidelines. Management of anxiety disorders","volume":"51","author":"Canadian Psychiatric Association","year":"2006","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/YIC.0b013e3283372977","article-title":"Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone","volume":"25","author":"Canuso","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0120","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/14656566.2020.1717466","article-title":"Pharmacological strategies for the management of comorbid depression and schizophrenia","volume":"21","author":"Ceskova","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.schres.2024.05.020_bb0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2007-1014355","article-title":"Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses","volume":"26","author":"Ceskov\u00e1","year":"1993","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0130","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.v69n0505","article-title":"Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial","volume":"69","author":"Chang","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0135","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1440-1819.2001.00879.x","article-title":"Correlation of panic attacks and hostility in chronic schizophrenia","volume":"55","author":"Chen","year":"2001","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2024.05.020_bb0140","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1017\/S1092852900015704","article-title":"Comorbidity with axis I anxiety disorders in remitted psychotic patients 1 year after hospitalization","volume":"12","author":"Ciapparelli","year":"2007","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2024.05.020_bb0145","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.schres.2024.05.020_bb0150","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder","volume":"158","author":"Conley","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.psychres.2015.11.027","article-title":"Attenuated positive psychotic symptoms and social anxiety: along a psychotic continuum or different constructs?","volume":"235","author":"Cooper","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","article-title":"Comparative pharmacology of risperidone and paliperidone","volume":"15","author":"Corena-McLeod","year":"2015","journal-title":"Drugs R D"},{"key":"10.1016\/j.schres.2024.05.020_bb0165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.brainres.2008.07.021","article-title":"Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression","volume":"1233","author":"Corena-McLeod","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0170","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial","volume":"172","author":"Correll","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0175","series-title":"Covidence: Better Systematic Review Management","author":"Covidence","year":"2020"},{"key":"10.1016\/j.schres.2024.05.020_bb0180","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bph.13346","article-title":"Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models","volume":"173","author":"Cross","year":"2016","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2024.05.020_bb0190","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bdi.13125","article-title":"Efficacy and acceptability of pharmacotherapy for comorbid anxiety symptoms in bipolar disorder: a systematic review and meta-analysis","volume":"23","author":"Cullen","year":"2021","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.schres.2024.05.020_bb0195","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4088\/JCP.07r03618","article-title":"Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis","volume":"70","author":"Cunill","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0200","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.520","article-title":"Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study","volume":"6","author":"Davis","year":"2016","journal-title":"Brain Behav."},{"key":"10.1016\/j.schres.2024.05.020_bb0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.pneurobio.2016.03.004","article-title":"Serotonergic modulation of the activity of mesencephalic dopaminergic systems: therapeutic implications","volume":"151","author":"De Deurwaerd\u00e8re","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.schres.2024.05.020_bb0215","series-title":"Statistical Algorithms in Review Manager","first-page":"1","article-title":"Statistical methods group of the Cochrane Collaboration","volume":"5","author":"Deeks","year":"2007"},{"key":"10.1016\/j.schres.2024.05.020_bb0220","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2","article-title":"Analysing data and undertaking meta-analyses","author":"Deeks","year":"2011"},{"key":"10.1016\/j.schres.2024.05.020_bb0225","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2007-1014494","article-title":"Amisulpride versus haloperidol in treatment of schizophrenic patients\u2013results of a double-blind study","volume":"23","author":"Delcker","year":"1990","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0230","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.v65n0803","article-title":"A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors","volume":"65","author":"Denys","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0235","article-title":"Benzodiazepines for schizophrenia","volume":"2012","author":"Dold","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2024.05.020_bb0240","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5152\/alphapsychiatry.2023.221030","article-title":"Exploring the \u201cinsight paradox\u201d in treatment-resistant schizophrenia: correlations between dimensions of insight and depressive symptoms in patients receiving clozapine","volume":"24","author":"D\u00f6nmezler","year":"2023","journal-title":"Alpha Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079906X162809","article-title":"Quetiapine augmentation of treatment-resistant depression: a comparison with lithium","volume":"23","author":"Dor\u00e9e","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.schres.2024.05.020_bb0250","series-title":"Effect Sizes Based on Correlations","first-page":"41","year":"2009"},{"key":"10.1016\/j.schres.2024.05.020_bb0255","series-title":"Effect Sizes Based on Means","first-page":"21","year":"2009"},{"key":"10.1016\/j.schres.2024.05.020_bb0260","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2024.05.020_bb0265","first-page":"11","article-title":"Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"20","author":"Fleischhacker","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0270","doi-asserted-by":"crossref","first-page":"3084859","DOI":"10.1155\/2017\/3084859","article-title":"Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews","volume":"2017","author":"Fornaro","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.schres.2024.05.020_bb0275","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1600-0447.1974.tb09706.x","article-title":"Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia","volume":"50","author":"Gerlach","year":"1974","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2024.05.020_bb0280","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4088\/JCP.v66n0205","article-title":"Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists","volume":"66","author":"Goff","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0285","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14732","article-title":"The effect of lurasidone on anxiety symptoms in patients with bipolar depression: a post hoc analysis","volume":"84","author":"Goldberg","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0290","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.schres.2024.05.020_bb0295","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/NMD.0b013e31802c1424","article-title":"Neurocognitive deterioration in elderly chronic schizophrenia patients with and without PTSD","volume":"195","author":"Goodman","year":"2007","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2024.05.020_bb0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1034\/j.1600-0447.2002._10424.x","article-title":"Panic attacks in psychosis","volume":"105","author":"Goodwin","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2024.05.020_bb0305","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-9964(02)00292-X","article-title":"Anxiety and substance use comorbidity among inpatients with schizophrenia","volume":"61","author":"Goodwin","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0310","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","article-title":"Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"25","author":"Gopal","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0315","doi-asserted-by":"crossref","first-page":"9532","DOI":"10.3390\/ijms21249532","article-title":"Mechanism of action of atypical antipsychotic drugs in mood disorders","volume":"21","author":"Grinchii","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.schres.2024.05.020_bb0320","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2024.05.020_bb0325","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.schres.2024.05.020_bb0330","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004714-200302000-00003","article-title":"Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy","volume":"23","author":"Hamner","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0335","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5152\/alphapsychiatry.2022.21629","article-title":"Optical coherence tomography angiography in schizophrenia","volume":"23","author":"Hanifi Koka\u00e7ya","year":"2022","journal-title":"Alpha Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0340","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/acps.12080","article-title":"Anxiety and depression in psychosis: a systematic review of associations with positive psychotic symptoms","volume":"128","author":"Hartley","year":"2013","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2024.05.020_bb0345","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-009-1626-0","article-title":"The 5-HT7 receptor and disorders of the nervous system: an overview","volume":"206","author":"Hedlund","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2024.05.020_bb0350","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","article-title":"Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis","volume":"173","author":"Helfer","year":"2016","journal-title":"AJP"},{"key":"10.1016\/j.schres.2024.05.020_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112769","article-title":"Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex","volume":"393","author":"Hereta","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0360","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40263-014-0162-6","article-title":"Role of atypical antipsychotics in the treatment of generalized anxiety disorder","volume":"28","author":"Hershenberg","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2024.05.020_bb0365","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (Updated March 2011)","author":"Higgins","year":"2011"},{"key":"10.1016\/j.schres.2024.05.020_bb0370","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2024.05.020_bb0375","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0380","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1017\/S109285290001676X","article-title":"Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder","volume":"13","author":"Hoge","year":"2008","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2024.05.020_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2628","article-title":"Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review","volume":"32","author":"Howells","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0390","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1176\/jnp.12.1.91","article-title":"Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study","volume":"12","author":"Hwang","year":"2000","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2024.05.020_bb0395","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2024.05.020_bb0400","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/JCP.0000000000000710","article-title":"Aripiprazole once-monthly in the treatment of acute psychotic episodes in schizophrenia: post hoc analysis of Positive and Negative Syndrome Scale Marder Factor Scores","volume":"37","author":"Ismail","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0405","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/pcn.13221","article-title":"Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled study","volume":"75","author":"Iyo","year":"2021","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2024.05.020_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.schres.2024.05.020_bb0415","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.pharep.2016.04.002","article-title":"Lurasidone: the 2016 update on the pharmacology, efficacy and safety profile","volume":"68","author":"Jaeschke","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.schres.2024.05.020_bb0420","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/da.22854","article-title":"Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders","volume":"36","author":"Jakubovski","year":"2019","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.schres.2024.05.020_bb0425","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","article-title":"Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties","volume":"244","author":"Janssen","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2024.05.020_bb0430","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.05.020_bb0435","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine\u2019s antidepressant activity","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.schres.2024.05.020_bb0440","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0091-3057(01)00745-6","article-title":"The medical benefit of 5-HT research","volume":"71","author":"Jones","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.schres.2024.05.020_bb0445","doi-asserted-by":"crossref","first-page":"383","DOI":"10.5414\/CPP48383","article-title":"Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia","volume":"48","author":"Jones","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2024.05.020_bb0450","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.euroneuro.2014.06.014","article-title":"Treatment with ziprasidone for schizophrenia patients with OCD","volume":"24","author":"Juven-Wetzler","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0455","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archpsyc.58.10.965","article-title":"Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison","volume":"58","author":"Kane","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0460","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0465","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","article-title":"Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia","volume":"30","author":"Kane","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0470","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4088\/JCP.10m06306","article-title":"A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment","volume":"72","author":"Kane","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0475","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.4088\/JCP.14m09168","article-title":"Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study","volume":"75","author":"Kane","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0480","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","author":"Kane","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0485","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"AJP"},{"key":"10.1016\/j.schres.2024.05.020_bb0490","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3371\/CSRP.KARA.070415","article-title":"Add-on Pregnenolone with L-theanine to antipsychotic therapy relieves negative and anxiety symptoms of schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial","volume":"12","author":"Kardashev","year":"2018","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.schres.2024.05.020_bb0495","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0165-0327(11)70004-0","article-title":"Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness","volume":"128","author":"Katzman","year":"2011","journal-title":"J. Affect. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2024.05.020_bb0500","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0505","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.05.020_bb0510","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S2045796017000270","article-title":"Symptom rating scales for schizophrenia and other primary psychotic disorders in ICD-11","volume":"27","author":"Keeley","year":"2018","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.schres.2024.05.020_bb0515","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0520","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1192\/bjp.bp.105.017020","article-title":"Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study","volume":"191","author":"Keks","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0525","doi-asserted-by":"crossref","first-page":"A21","DOI":"10.1097\/00004850-200607000-00064","article-title":"The efficacy of perospirone for the treatment of anxiety and depressive symptoms in schizophrenia","volume":"21","author":"Kikuyama","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0530","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.pnpbp.2007.07.005","article-title":"Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial","volume":"31","author":"Kim","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0535","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s002130050603","article-title":"A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia","volume":"137","author":"King","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2024.05.020_bb0540","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajem.2004.02.021","article-title":"Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia","volume":"22","author":"Kinon","year":"2004","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.schres.2024.05.020_bb0545","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0022-3565(24)38019-X","article-title":"Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens","volume":"288","author":"Kuroki","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2024.05.020_bb0550","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0079-6123(08)00910-2","article-title":"Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis","volume":"172","author":"Kuroki","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0555","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1523\/JNEUROSCI.1790-05.2005","article-title":"5-HT7 receptor is coupled to G\u03b1 subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology","volume":"25","author":"Kvachnina","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2024.05.020_bb0560","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m13906","article-title":"PANSS individual item and Marder dimension analyses from a pivotal trial of RBP-7000 (monthly extended-release risperidone) in schizophrenia patients","volume":"82","author":"Le Moigne","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0565","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.05.020_bb0570","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-2007-1014288","article-title":"Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol","volume":"27","author":"Lindstr\u00f6m","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0575","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0278-5846(03)00039-3","article-title":"Obsessive\u2013compulsive symptoms induced by atypical antipsychotics. A review of the reported cases","volume":"27","author":"Lykouras","year":"2003","journal-title":"Progr. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0580","first-page":"28","article-title":"Lifetime prevalence of mood and anxiety disorders in twin pairs discordant for schizophrenia","volume":"3","author":"Lyons","year":"2000","journal-title":"Twin Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0585","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0590","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1176\/appi.ajp.160.8.1405","article-title":"Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes","volume":"160","author":"Marder","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0595","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study","volume":"62","author":"Marder","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0600","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1038\/s41380-020-0711-y","article-title":"GABA-A receptor differences in schizophrenia: a positron emission tomography study using [11C]Ro154513","volume":"26","author":"Marques","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0605","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/13651500500487586","article-title":"A benzisothiazole derivative and antipsychotic agent, perospirone, for augmentation of selective serotonin reuptake inhibitors (SSRIs) in refractory obsessive-compulsive disorder (OCD): two patient case series","volume":"10","author":"Matsunaga","year":"2006","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.schres.2024.05.020_bb0610","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.WNF.0000220819.71231.96","article-title":"A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia","volume":"29","author":"Mauri","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0615","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J."},{"key":"10.1016\/j.schres.2024.05.020_bb0620","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/0020764008093447","article-title":"Co-morbid social phobia in schizophrenia","volume":"55","author":"Mazeh","year":"2009","journal-title":"Int. J. Soc. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0625","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.biopsych.2023.04.004","article-title":"Data-driven taxonomy for antipsychotic medication: a new classification system","volume":"94","author":"McCutcheon","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0630","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.schres.2024.05.020_bb0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-002-1088-0","article-title":"Commentary on \u201cclinical studies on the mechanism of action of clozapine; the dopamine-serotonin hypothesis of schizophrenia.\u201d Psychopharmacology (1989) 99:S18\u2013S27","volume":"163","author":"Meltzer","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2024.05.020_bb0640","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","article-title":"Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics","volume":"176","author":"Misawa","year":"2016","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2024.05.020_bb0645","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ijnp\/pyaa082","article-title":"Antidepressive effect of antipsychotics in the treatment of schizophrenia: meta-regression analysis of randomized placebo-controlled trials","volume":"24","author":"Miura","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0650","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/j.1471-4159.1990.tb01230.x","article-title":"Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study","volume":"54","author":"Moghaddam","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2024.05.020_bb0655","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF02922257","article-title":"Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland","volume":"247","author":"M\u00f6ller","year":"1997","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2024.05.020_bb0660","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00004714-200212000-00004","article-title":"Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia","volume":"22","author":"M\u00fcller","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0665","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ijnp\/pyab071","article-title":"A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia","volume":"25","author":"Najarian","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0670","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/npp.2010.79","article-title":"A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia","volume":"35","author":"Nasrallah","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2024.05.020_bb0675","doi-asserted-by":"crossref","first-page":"pyv111","DOI":"10.1093\/ijnp\/pyv111","article-title":"Brexpiprazole alters monoaminergic systems following repeated administration: an in vivo electrophysiological study","volume":"19","author":"Oosterhof","year":"2016","journal-title":"IJNPPY"},{"key":"10.1016\/j.schres.2024.05.020_bb0680","doi-asserted-by":"crossref","first-page":"10624","DOI":"10.3390\/ijms231810624","article-title":"New atypical antipsychotics in the treatment of schizophrenia and depression","volume":"23","author":"Orzelska-G\u00f3rka","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.schres.2024.05.020_bb0685","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pnpbp.2006.10.014","article-title":"Perospirone augmentation of paroxetine in treatment of refractory obsessive\u2013compulsive disorder with depression","volume":"31","author":"Otsuka","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0690","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"key":"10.1016\/j.schres.2024.05.020_bb0695","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1192\/bjp.186.5.386","article-title":"Pathogenesis of schizophrenia: a psychopathological perspective","volume":"186","author":"Owens","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0700","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00023210-200822050-00002","article-title":"Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence","volume":"22","author":"Pae","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2024.05.020_bb0705","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2024.05.020_bb0710","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1017\/S1092852900021635","article-title":"Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine","volume":"5","author":"Pallanti","year":"2000","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2024.05.020_bb0715","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1176\/appi.ajp.161.1.53","article-title":"Social anxiety in outpatients with schizophrenia: a relevant cause of disability","volume":"161","author":"Pallanti","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0720","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0725","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0730","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0166-2236(95)80023-U","article-title":"5-HT receptors: past, present and future","volume":"18","author":"Peroutka","year":"1995","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.schres.2024.05.020_bb0735","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","article-title":"Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2\/D3 dopamine receptor antagonist activity and limbic selectivity","volume":"280","author":"Perrault","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2024.05.020_bb0740","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1192\/bjp.166.6.712","article-title":"Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group","volume":"166","author":"Peuskens","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0745","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-1781(99)00075-X","article-title":"Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group","volume":"88","author":"Peuskens","year":"1999","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0750","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/157340006778018193","article-title":"Prevalence of comorbid anxiety disorders in schizophrenia spectrum disorders: a literature review","volume":"2","author":"Pokos","year":"2006","journal-title":"Curr. Psychiatr. Rev."},{"key":"10.1016\/j.schres.2024.05.020_bb0755","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopsych.2005.07.005","article-title":"Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study","volume":"59","author":"Pollack","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0760","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0165-1781(01)00238-4","article-title":"Obsessive-compulsive disorder in hospitalized patients with chronic schizophrenia","volume":"102","author":"Poyurovsky","year":"2001","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0765","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1998.tb10044.x","article-title":"Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group","volume":"98","author":"Puech","year":"1998","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2024.05.020_bb0770","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.psychres.2013.01.012","article-title":"Depression and social anxiety in help-seeking patients with an ultra-high risk for developing psychosis","volume":"209","author":"Rietdijk","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0775","doi-asserted-by":"crossref","first-page":"10913","DOI":"10.4088\/JCP.09m05031yel","article-title":"L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study","volume":"71","author":"Ritsner","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0780","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-021-01000-1","article-title":"Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects","volume":"41","author":"Rognoni","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.schres.2024.05.020_bb0785","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.schres.2024.05.020_bb0790","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0091-3057(98)00068-9","article-title":"Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent","volume":"60","author":"Sakamoto","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.schres.2024.05.020_bb0795","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00213-015-4002-2","article-title":"Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers","volume":"232","author":"Sato","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2024.05.020_bb0800","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile","volume":"425","author":"Schmidt","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0805","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2024.05.020_bb0810","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)12023-5","article-title":"Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity","volume":"275","author":"Seeger","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2024.05.020_bb0815","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/01.jcp.0000236659.93415.4a","article-title":"Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain","volume":"26","author":"Sekine","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0820","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.schres.2006.09.023","article-title":"Suicidality in schizophrenic patients with and without obsessive-compulsive disorder","volume":"90","author":"Sevincok","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0825","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0830","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0006-3223(99)00273-5","article-title":"Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo","volume":"47","author":"Sharpley","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0835","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/00005053-199707000-00003","article-title":"The phenomenology of traumatic reactions to psychotic illness","volume":"185","author":"Shaw","year":"1997","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2024.05.020_bb0840","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1254\/jphs.93.114","article-title":"Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HT1A receptor","volume":"93","author":"Shiwa","year":"2003","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.schres.2024.05.020_bb0845","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4088\/JCP.v67n0307","article-title":"An open-label trial of risperidone augmentation for refractory anxiety disorders","volume":"67","author":"Simon","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0850","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.4088\/JCP.v67n0804","article-title":"A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder","volume":"67","author":"Simpson","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0855","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.schres.2006.11.009","article-title":"The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined","volume":"90","author":"Skilbeck","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0860","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/01.jcp.0000177853.15910.de","article-title":"Open-label pilot study of ziprasidone for refractory generalized anxiety disorder","volume":"25","author":"Snyderman","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852915000954","article-title":"Mechanism of action of brexpiprazole: comparison with aripiprazole","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2024.05.020_bb0870","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3390\/molecules23082087","article-title":"Current concepts and treatments of schizophrenia","volume":"23","author":"St\u0119pnicki","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.schres.2024.05.020_bb0875","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/jpet.102.033282","article-title":"Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT2A receptor antagonism on the firing activity of norepinephrine neurons","volume":"302","author":"Szabo","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2024.05.020_bb0880","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0920-9964(00)00126-2","article-title":"The Schizophrenia Suicide Risk Scale (SSRS): development and initial validation","volume":"47","author":"Taiminen","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0885","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.2147\/NDT.S54051","article-title":"Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia","volume":"9","author":"Takahashi","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2024.05.020_bb0890","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pnpbp.2012.09.010","article-title":"A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients","volume":"40","author":"Takekita","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2024.05.020_bb0895","first-page":"4","article-title":"Antipsychotics in the treatment of schizophrenia: an overview","volume":"72","author":"Tandon","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0900","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00127-010-0277-0","article-title":"Co-morbid PTSD and suicidality in individuals with schizophrenia and substance and alcohol abuse","volume":"46","author":"Tarrier","year":"2011","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.schres.2024.05.020_bb0905","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/NDT.S185815","article-title":"Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies","volume":"15","author":"Thase","year":"2018","journal-title":"NDT"},{"key":"10.1016\/j.schres.2024.05.020_bb0910","series-title":"The Cochrane Collaboration: Review Manager","year":"2020"},{"key":"10.1016\/j.schres.2024.05.020_bb0915","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0006-3223(98)00093-6","article-title":"A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia","volume":"43","author":"Tollefson","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0920","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00002018-200427140-00005","article-title":"Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents","volume":"27","author":"Toren","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.schres.2024.05.020_bb0925","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.bmc.2011.02.033","article-title":"Molecular properties affecting fast dissociation from the D2 receptor","volume":"19","author":"Tresadern","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.schres.2024.05.020_bb0930","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1017\/S1092852917000074","article-title":"Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study","volume":"22","author":"Tsai","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2024.05.020_bb0935","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.pnpbp.2010.07.014","article-title":"Impact of panic attacks on quality of life among patients with schizophrenia","volume":"34","author":"Ula\u015f","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0940","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JCP.0b013e318166f520","article-title":"Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis","volume":"28","author":"van Nimwegen","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0945","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.05.020_bb0950","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eurpsy.2006.09.003","article-title":"A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression","volume":"21","author":"Vanelle","year":"2006","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0955","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40261-017-0592-2","article-title":"A review of asenapine in the treatment of bipolar disorder","volume":"38","author":"Vieta","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.schres.2024.05.020_bb0960","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4183\/aeb.2010.265","article-title":"A novel approach on pharmacokinetic\/pharmacodynamic correlations of risperidone: understanding its safety and efficacy profiles","volume":"6","author":"Voicu","year":"2010","journal-title":"Acta Endo (Buc)"},{"key":"10.1016\/j.schres.2024.05.020_bb0965","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jpsychires.2006.03.008","article-title":"Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study","volume":"40","author":"Wang","year":"2006","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0970","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1734-1140(10)70315-7","article-title":"Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data","volume":"62","author":"Weso\u0142owska","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.schres.2024.05.020_bb0975","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.comppsych.2005.08.007","article-title":"Comorbidity patterns in routine psychiatric practice: is there evidence of underdetection and underdiagnosis?","volume":"47","author":"Wilk","year":"2006","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.schres.2024.05.020_bb0980","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/0269881111405555","article-title":"Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients","volume":"26","author":"Yasui-Furukori","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.05.020_bb0985","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0920-9964(02)00167-6","article-title":"Psychosis prediction: 12-month follow up of a high-risk (\u201cprodromal\u201d) group","volume":"60","author":"Yung","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.05.020_bb0990","article-title":"Augmentation with antidepressants in schizophrenia treatment: benefit or risk","volume":"701","author":"Zhang","year":"2015","journal-title":"NDT"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424002068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424002068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:38:23Z","timestamp":1762317503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424002068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":198,"alternative-id":["S0920996424002068"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.05.020","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of second-generation antipsychotics on anxiety\/depression in patients with schizophrenia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}